Dencatistat - Step Pharma
Alternative Names: CTPS1 inhibitor - Step Pharma; STP 938Latest Information Update: 23 Feb 2026
At a glance
- Originator Step Pharma
- Class Anti-inflammatories; Antineoplastics; Antirheumatics; Antithrombotics; Small molecules
- Mechanism of Action CTPS1 protein inhibitors
-
Orphan Drug Status
Yes - T-cell lymphoma
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I/II B-cell lymphoma; T-cell lymphoma
- Phase I Solid tumours; Thrombocytosis
- Preclinical Graft-versus-host disease; Inflammation
- No development reported Rheumatoid arthritis
Most Recent Events
- 23 Feb 2026 Step Pharma plans phase II trials for Gynaecological cancer
- 10 Feb 2026 Preclinical development in Inflammation is till ongoing in France (PO) (Step Pharma pipeline, February 2026)
- 15 Oct 2025 Adverse event data from a phase I/II trial in T-cell lymphoma/B-cell lymphoma released by Step Pharma